Gamgee, a mobile health firm keeping a low profile, has revealed in a SEC filing that it has attracted $2 million in funds from Khosla Ventures.
The firm is headed by Bob Quinn (pictured), the former CTO of Epocrates, the company behind a popular app which offers drug information to the medical profession.
So far, information is scarce on Quinn’s new venture although his LinkedIn profile does reveal a big ambition: “Funded by Khosla Ventures, I am building an exciting new mobile healthcare company. Near-term, our goal is to get a very helpful mobile healthcare app used by millions of people who are chronically ill or headed that way.
We are confident that we know how to do this. Long-term, we will change the way people get their healthcare questions answered.”
Vinod Khosla himself is not immune to big visions either, or controversial ones. He commented last year that “80 percent of what doctors can do can be replaced”, as part of his radical, patient-centric view of healthcare. Mobile technology is a big part of the vision.
Khosla has invested in Jawbone, Zyomed, Cellscope, Misfit Wearables, Verifica-BG, Alivecor and, most recently, HealthTap.